The Endocrine Society has launched a Diabetes SIG to centralize expertise and networking for clinicians and researchers devoted to diabetes. The announcement named the SIG as a forum where endocrinologists, investigators, educators, and trainees will convene. The SIG will run regularly scheduled webinars and maintain continuous peer-to-peer discussion threads on EndoForum, allowing members to solicit advice and share observations from any location. The source did not report membership numbers, selection criteria for SIG leaders, or formal governance documents.
The Society’s educational calendar contains multiple diabetes-focused offerings. Recordings from Clinical Endocrinology Update (CEU) 2026 include eight sessions that span practical and scientific topics: immune checkpoint-related endocrine complications, diabetes in pregnancy, once-weekly insulin innovations, pathogenesis of type 1 diabetes, peripheral vascular disease screening, intermittent fasting implications, and diabetes technology such as pumps and CGMs. Short sessions delivered clinical updates; longer ones explored mechanistic questions and guideline-aligned management approaches. The source provided session titles but did not include speaker lists or detailed learning objectives.
The competitive Type 1 Diabetes Fellows Series completed its 13th year in 2026. This program aims to support endocrine fellows entering diabetes-focused careers. The article asked readers to check the fellows webpage for the 2027 application cycle; specific application dates or selection processes were not provided.
ENDO programming also addressed pregnancy and type 1 diabetes. During ENDO 2026, a session presented data on pregnancy risks in women with type 1 diabetes, including fetal overgrowth concerns; that work was featured on an Endocrine News podcast. The Society will introduce the Jesse Roth Award Lecture at ENDO 2027, honoring a leader in insulin receptor research and intended to showcase significant clinical and research contributions.
The Society’s Center for Learning hosts course recordings and standalone modules relevant to diabetes. The source listed offerings such as "Using Diabetes Technology in Pregnancy" and a module on obesity across generations—but it did not report CME credit details or enrollment figures. Written tools remain prominent. ESAP 2026 dedicated 30 cases to diabetes; Endocrine Board Review (EBR) 2026 provided 52 diabetes cases; and the Meet the Professor (MTP) 2026 volume included six diabetes chapters covering diabetic kidney disease, diabetes across reproductive life stages, youth-onset type 2 transition, adjunctive therapies in type 1 diabetes, inpatient hyperglycemia management, and GLP-1 receptor agonist safety questions. The Society also publishes Endocrine Education Cases Flashcards with 57 diabetes treatment cards for trainees.
The Society’s journals continue to publish diabetes research across clinical and translational domains. The article listed high-Altmetric-topic papers from 2026, including studies on GLP-1 receptor agonists and fracture risk, ketogenic diets and proinsulin–C-peptide ratios, social inequalities in gestational diabetes, semaglutide in latent autoimmune diabetes in adults, and time-in-range declines linked to microvascular complications in type 1 diabetes. These items feed into an annual thematic issue; this year’s April edition focused on obesity and metabolic health, with diet and appetite regulation papers drawn from multiple Society journals. The source named topics and titles but did not provide citation details or impact metrics beyond Altmetric mention.
Advocacy emerged as a core Society activity. The organization described ongoing efforts on Capitol Hill aimed at expanding access to affordable insulin beyond Medicare populations. The Society credited prior advocacy with helping lower insulin costs for Medicare beneficiaries and said it is pursuing policies for privately insured and uninsured patients. The article described the launch of a Diabetes Advocacy Campaign focused on reauthorizing the Special Diabetes Program (SDP) and supporting passage of the INSULIN Act. The source did not provide legislative timelines, quantitative advocacy outcomes, or specifics about stakeholder engagements.
Beyond formal education and advocacy, the Society promotes community and identity among members. The online store offers themed merchandise—pancreas socks, keychains, lapel pins, and plushies—designed to foster member engagement and lighten professional camaraderie. The article positioned these items as fun, morale-building additions to the Society’s portfolio. No sales figures or uptake statistics were included in the source.
The Society encouraged members to use the new SIG and existing learning platforms to expand clinical expertise and research networks. Specific next steps documented in the source include checking the fellows webpage for the 2027 application cycle and engaging with the Diabetes Advocacy Campaign to support SDP reauthorization and the INSULIN Act. The article did not provide deadlines for these efforts, measurable targets for advocacy success, or operational details for SIG activities. These outstanding questions—application timelines, SIG governance, and the legislative schedule for the SDP and insulin affordability bills—represent concrete items for members to monitor in coming months.